Hepatitis Monthly

Published by: Kowsar

The CCR5-∆32 Mutation: Impact on Disease Outcome in Individuals with Hepatitis B Infection in the Southern Khorasan Population (East of Iran)

Hamidreza Safari 1 , Gholamreza Anani Sarab 2 , Mohammad Fereidouni 3 , Masood Ziaee 2 , Neda Mahavar 1 , Mohammad Sadegh Naghizadeh 1 , Abdolghader Taene 1 , Roya Mahdavi 4 and Mohsen Naseri 3 , *
Authors Information
1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2 Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
3 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
4 Department of Immunology, Birjand University of Medical Sciences, Birjand, Iran
Article information
  • Hepatitis Monthly: October 2017, 17 (10); e55014
  • Published Online: October 23, 2017
  • Article Type: Research Article
  • Received: June 14, 2017
  • Revised: September 3, 2017
  • Accepted: October 7, 2017
  • DOI: 10.5812/hepatmon.55014

To Cite: Safari H, Anani Sarab G, Fereidouni M, Ziaee M, Mahavar N, et al. The CCR5-∆32 Mutation: Impact on Disease Outcome in Individuals with Hepatitis B Infection in the Southern Khorasan Population (East of Iran), Hepat Mon. 2017 ;17(10):e55014. doi: 10.5812/hepatmon.55014.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Schinazi RF, Asselah T. From HCV To HBV Cure. Liver Int. 2017; 37 Suppl 1: 73-80[DOI][PubMed]
  • 2. Ziaee M, Azarkar G. Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012. Hepat Mon. 2013; 13(8)[DOI][PubMed]
  • 3. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4(3): 74-80[DOI][PubMed]
  • 4. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011; 17(2): 87-95[DOI][PubMed]
  • 5. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014; 98(1): 39-54[DOI][PubMed]
  • 6. Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, Derakhshan F, Chiani M, et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect. 2008; 14(9): 858-66[DOI][PubMed]
  • 7. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54: 1-31[PubMed]
  • 8. WHO . Introduction of hepatitis B vaccine into childhood immunization services. WHO. 2001;
  • 9. Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet. 2008; 35(3): 255-64[DOI][PubMed]
  • 10. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infect Genet Evol. 2016; 44: 94-105[DOI][PubMed]
  • 11. Tuncbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World J Gastroenterol. 2014; 20(20): 6226-35[DOI][PubMed]
  • 12. Zare-Bidaki M, Karimi-Googheri M, Hassanshahi G, Zainodini N, Arababadi MK. The frequency of CCR5 promoter polymorphisms and CCR5 Delta 32 mutation in Iranian populations. Iran J Basic Med Sci. 2015; 18(4): 312-6[PubMed]
  • 13. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 2006; 7(3): 264-8[DOI][PubMed]
  • 14. Bobyk KD, Mandadapu SR, Lohith K, Guzzo C, Bhargava A, Lusso P, et al. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations. Mol Pharm. 2017; 14(8): 2681-9[DOI][PubMed]
  • 15. Zulfiqar HF, Javed A, Afroze B, Ali Q, Akbar K, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017; 5: 32[DOI][PubMed]
  • 16. de Silva E, Stumpf MP. HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett. 2004; 241(1): 1-12[DOI][PubMed]
  • 17. Contopoulos-Ioannidis DG, O'Brien TR, Goedert JJ, Rosenberg PS, Ioannidis JP. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J Acquir Immune Defic Syndr. 2003; 32(1): 70-6[DOI][PubMed]
  • 18. Sanchooli J, Sanadgol N, Kazemi Arababadi M, Kennedy D. CCR5 plays important roles in hepatitis B infection. Viral Immunol. 2014; 27(1): 2-6[DOI][PubMed]
  • 19. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19(2): 174-7[DOI][PubMed]
  • 20. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett. 2005; 96(2): 277-81[DOI][PubMed]
  • 21. Ziaee M, Ebrahimzadeh A, Azarkar Z, Namaei MH, Saburi A, Fereidouni M, et al. Seroprevalence and Risk Factors for Hepatitis B in an Adult Population: The First Report from Birjand, South Khorasan, Iran. Hepat Mon. 2016; 16(9)[DOI][PubMed]
  • 22. Kazemi Arababadi M, Hassanshahi G, Azin H, Akbarpour Salehabad V, Araste M, Pourali R, et al. No association between CCR5-Δ32 mutation and multiple sclerosis in patients of southeastern Iran. Lab Med. 2010; 41(1): 31-3[DOI]
  • 23. Omrani MD, Bagheri M. Frequency of CCR5Δ32 variant in North-West of Iran. J Sci Islam Repub Iran. 2009; 20(2): 105-10[DOI]
  • 24. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol. 2005; 3(11)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader